4.7 Article

Hypoxemic Respiratory Failure Following Ruxolitinib Discontinuation in Allogeneic Hematopoietic Cell Transplantation Recipients

Journal

ONCOLOGIST
Volume 26, Issue 11, Pages E2082-E2085

Publisher

WILEY
DOI: 10.1002/onco.13903

Keywords

Ruxolitinib; Discontinuation; Hypoxemic respiratory failure; Allogeneic hematopoietic cell transplantation

Categories

Ask authors/readers for more resources

Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly used in allogeneic hematopoietic cell transplantation (HCT) recipients, with potential complications including acute hypoxemic respiratory failure upon discontinuation. However, systemic corticosteroids and reinitiation of ruxolitinib have shown to result in rapid clinical improvement in affected patients. Further research is necessary to characterize the biological and clinical effects of ruxolitinib discontinuation in this patient population.
Ruxolitinib, a selective inhibitor of Janus kinases 1 and 2, is increasingly being used in allogeneic hematopoietic cell transplantation (HCT) recipients following its approval by the U.S. Food and Drug Administration for the treatment of steroid-refractory acute graft-versus-host disease. Although there is extensive experience using ruxolitinib for patients with myeloproliferative neoplasms, the biologic effects and clinical implications of its dosing, tapering, and discontinuation for allogeneic HCT recipients are incompletely characterized. We describe three allogeneic HCT recipients who developed acute hypoxemic respiratory failure within 3 months of ruxolitinib discontinuation. Radiographic findings included marked bilateral ground-glass opacities. Systemic corticosteroids and reinitiation of ruxolitinib resulted in rapid clinical improvement in all three patients. All three patients achieved a significant clinical response, with decrease in oxygen requirement and improvement in radiographic changes. Given the increasing use of ruxolitinib in allogeneic HCT recipients, there is significant impetus to characterize the biologic and clinical effects resulting from discontinuation of ruxolitinib, to better tailor treatment plans and prevent potential adverse effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available